Clinical Trial Update: AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports on AB-101 as a monotherapy and in combination with immunotherapy for relapsed/refractory B-cell Non-Hodgkin Lymphoma in Phase…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• AB-101

Snippet

Sponsor: Artiva Biotherapeutics, Inc. | Conditions: Non Hodgkin Lymphoma | Phase 1, Phase 2 | Status: COMPLETED